Skip to main content

Table 2 Distribution of CYP2D6 genotype and predicted phenotype by different ethnic groups

From: Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

  Ethnicity  
CYP2D6predicted phenotype/genotype Caucasian Latina/Hispanic AA/Black Asian Pacific Islander Other/mixed Declined/missed Total N (%)
Ultra-rapid (UM) 8 (5%) 1 (7%) 0 1 (2%) 0 0 0 10 (4%)
   *1/*1 × N 5 0 0 0 0 0 0 5
   *1/*2 × N 1 1 0 0 0 0 0 2
   *2/*1 × N 1 0 0 1 0 0 0 2
   *2/*2 × N 1 0 0 0 0 0 0 1
Extensive (EM) 131 (79%) 9 (65%) 2 (100%) 36 (64%) 1 (100%) 3 (100%) 3 (100%) 185 (76%)
   *1/*1 19 2 1 2 1 1 0 26
   *1/*2 20 0 0 5 0 0 0 25
   *1/*3 2 0 0 0 0 0 0 2
   *1/*4 23 1 0 1 0 0 1 26
   *1/*5 3 0 0 1 0 1 0 5
   *1/*6 1 0 0 0 0 0 0 1
   *1/*9 4 2 0 0 0 0 0 6
   *1/*10 1 0 0 15 0 0 0 16
   *1/*17 1 0 1 0 0 0 0 2
   *1/*29 0 0 0 0 0 0 1 1
   *1/*35 2 0 0 0 0 0 0 2
   *1/*41 16 1 0 1 0 0 0 18
   *1 × N/*5 1 0 0 0 0 0 0 1
   *1 × N/*10 0 0 0 1 0 0 0 1
   *2/*2 5 0 0 0 0 0 0 5
   *2/*4 11 1 0 0 0 0 1 13
   *2/*5 1 0 0 0 0 0 0 1
   *2/*9 1 0 0 0 0 0 0 1
   *2/*10 0 1 0 10 0 0 0 11
   *2/*35 3 0 0 0 0 0 0 3
   *2/*41 5 0 0 0 0 0 0 5
   *2/*41 × N 1 0 0 0 0 0 0 1
   *2 × N/*4 1 0 0 0 0 0 0 1
   *2 × N/*9 1 0 0 0 0 0 0 1
   *3/*35 1 0 0 0 0 0 0 1
   *4/*35 5 0 0 0 0 0 0 5
   *5/*35 0 1 0 0 0 0 0 1
   *10/*35 1 0 0 0 0 0 0 1
   *17/*35 0 0 0 0 0 1 0 1
   *35/*41 1 0 0 0 0 0 0 1
   *35/*41 × N 1 0 0 0 0 0 0 1
Intermediate (IM) 15 (9%) 2 (14%) 0 15 (27%) 0 0 0 32 (13%)
   *4/*9 1 0 0 0 0 0 0 1
   *4/*10 2 0 0 0 0 0 0 2
   *4/*17 1 0 0 0 0 0 0 1
   *4/*41 6 1 0 0 0 0 0 7
   *5/*10 1 0 0 2 0 0 0 3
   *10/*10 0 0 0 13 0 0 0 13
   *10/*41 2 0 0 0 0 0 0 2
   *29/*41 0 1 0 0 0 0 0 1
   *41/*41 2 0 0 0 0 0 0 2
Poor (PM) 10 (6%) 2 (14%) 0 1 (2%) 0 0 0 13 (5%)
   *3/*4 1 0 0 0 0 0 0 1
   *4/*4 7 0 0 1 0 0 0 8
   *4/*5 0 2 0 0 0 0 0 2
   *4/*6 1 0 0 0 0 0 0 1
   *4/*7 1 0 0 0 0 0 0 1
No genotype 2 (1%) 0 0 3 (5%) 0 0 0 5 (2%)
Total 166 14 2 56 1 3 3 245
  1. AA, African American; EM, extensive metabolizer; IM, intermediate metabolizer; N, number of participants in the study; PM, poor metabolizer; UM, ultra-rapid metabolizer.